BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 21665080)

  • 1. [Pleomorphic carcinoma of the lung: a case report].
    Tazi EM; Essadi I; Arifi S; Ichou M; Errihani H
    Rev Pneumol Clin; 2011 Jun; 67(3):163-6. PubMed ID: 21665080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A rare primary pulmonary tumor: pleomorphic carcinoma].
    Yangui I; Smaoui M; Khabir A; Ayoub A; Boudawara T
    Presse Med; 2007 Feb; 36(2 Pt 1):243-6. PubMed ID: 17259034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemo-radiotherapy in stage III non-small cell lung cancer: final results of an international phase II trial.
    Krzakowski M; Provencio M; Utracka-Hutka B; Villa E; Codes M; Kuten A; Henke M; Lopez M; Bell D; Biti G; Merimsky O; Beorchia A; Riggi M; Caux NR; Pouget JC; Dubray B; David P
    J Thorac Oncol; 2008 Sep; 3(9):994-1002. PubMed ID: 18758302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
    Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
    Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A radical resection of non-small cell lung cancer invading chest wall with ipsilateral axillary lymph node metastases].
    Watanabe N; Iwazawa T; Kitahara T; Yanagawa T; Munakata K; Takamoto K; Nagai K; Miyake M; Hata T; Kawanishi K; Shimizu J; Ikeda K; Fujita J; Akagi K; Dono K; Kitada M; Takimoto N; Abe K; Adachi S; Shimano T
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):991-4. PubMed ID: 21677493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I/II trial of neoadjuvant chemotherapy with cisplatin and vinorelbine followed by accelerated irradiation for patients with inoperable nonsmall cell lung carcinoma.
    Viallet J; Brassard MA; Souhami L; Ayoub J; Del Vecchio P; Kreisman H; Guerra J; Gruber J; Langleben A; Hohneker J; Rousseau P
    Cancer; 1999 Jun; 85(12):2562-9. PubMed ID: 10375103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).
    Belani CP; Fossella F
    Cancer; 2005 Dec; 104(12):2766-74. PubMed ID: 16288485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin and ifosfamide with various doses of vinorelbine (navelbine) in advanced non-small lung cancer.
    Souquet PJ; Fournel P; Bohas CH; Fortune IC; Chatte G
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):8-10. PubMed ID: 8610239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential chemoradiation therapy with vinorelbine, ifosfamide, and cisplatin in stage IIIB non-small cell lung cancer: a phase II study.
    Baldini E; Silvano G; Tibaldi C; Campoccia S; Cionini L; Conte P
    Semin Oncol; 2000 Feb; 27(1 Suppl 1):28-32. PubMed ID: 10697041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience.
    Mir O; Alexandre J; Ropert S; Montheil V; Martin I; Durand JP; Goldwasser F
    Anticancer Drugs; 2009 Feb; 20(2):105-8. PubMed ID: 19209026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin plus vinorelbine as induction chemotherapy followed by surgery in the treatment of stage IIIB non-small cell lung cancer. Final results of a multicenter phase II study.
    Cigolari S; Curcio C; Maiorino A; Sessa R; Cioffi A; Massimo M
    Anticancer Res; 2003; 23(2C):1803-9. PubMed ID: 12820462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
    Katsaounis P; Kotsakis A; Agelaki S; Kontopodis E; Agelidou A; Kentepozidis N; Vamvakas L; Christopoulou A; Karachaliou N; Hatzidaki D; Georgoulias V
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):821-7. PubMed ID: 25702051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction chemotherapy with cetuximab, vinorelbine-cisplatin followed by thoracic radiotherapy and concurrent cetuximab, vinorelbine-cisplatin in patients with unresectable stage III non-small cell lung cancer.
    Liu D; Zheng X; Chen J; Liu G; Xu Y; Shen Y; Xie L; Zhao W; Jiang G; Fan M
    Lung Cancer; 2015 Sep; 89(3):249-54. PubMed ID: 26118463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous non-small-cell lung cancer: final results of an International randomized phase II study (NAVotrial 01).
    Bennouna J; Havel L; Krzakowski M; Kollmeier J; Gervais R; Dansin E; Serke M; Favaretto A; Szczesna A; Cobo M; Ciuffreda L; Jassem J; Nicolini M; Ramlau R; Amoroso D; Melotti B; Almodovar T; Riggi M; Caux NR; Vaissière N; Tan EH
    Clin Lung Cancer; 2014 Jul; 15(4):258-65. PubMed ID: 24954228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC.
    Kim SH; Cho BC; Choi HJ; Chung KY; Kim DJ; Park MS; Kim SK; Chang J; Shin SJ; Sohn JH; Kim JH
    Lung Cancer; 2008 Jun; 60(3):393-400. PubMed ID: 18155802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Two younger male patients with rapidly progressing pulmonary pleomorphic carcinoma].
    Aketa A; Yamada G; Aketa K; Ohnishi T; Takahashi Y; Kudoh K; Tanaka S; Shiratori M; Takahashi H; Watanabe A; Satoh M; Abe S
    Nihon Kokyuki Gakkai Zasshi; 2004 Feb; 42(2):164-9. PubMed ID: 15007917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine.
    Viñolas N; Provencio M; Reguart N; Cardenal F; Alberola V; Sánchez-Torres JM; Barón FJ; Cobo M; Maestu I; Moreno I; Mesía C; Izquierdo A; Felip E; López-Brea M; Márquez A; Sánchez-Ronco M; Tarón M; Santarpia MC; Rosell R;
    Lung Cancer; 2011 Feb; 71(2):191-8. PubMed ID: 20627363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
    Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
    J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC.
    Lena MD; Ramlau R; Hansen O; Lorusso V; Wagner L; Barni S; Cristovao MM; Huber R; Alberola V; Mitrovic M; Colin C; Gasmi J
    Lung Cancer; 2005 Apr; 48(1):129-35. PubMed ID: 15777980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.